Acelyrin's IPO Success: Valued at $2.1 Billion with 28% Stock Jump.
TL;DR Summary
Biopharma company Acelyrin Inc. had a strong market debut on Nasdaq, with shares rising 28% and giving the company a market capitalization of $2.1 billion. The Los Angeles-based company raised $540 million by selling 30 million shares in an upsized offering. Acelyrin joins a spate of new listings recently that have fueled hopes of a recovery in IPO markets, including Johnson & Johnson's consumer health business Kenvue Inc.
- Biopharma firm Acelyrin valued at $2.1 billion in strong market debut Reuters
- Acelyrin sets out massive $540M upsized IPO FierceBiotech
- Acelyrin Raises $540M In IPO, Stock Gains Over 20% In Trading Debut Yahoo Finance
- Acelyrin Shares Jump 28% in Debut After Upsized IPO MarketWatch
- Acelyrin makes a splash with IPO, biopharma expects to raise $540M MM+M Online
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
56%
153 → 68 words
Want the full story? Read the original article
Read on Reuters